Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2022-11-03 00:00:00 ET · period of report 2022-11-01 · accession 0000899243-22-035038 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-11-03 | 2022-11-01 | LGND | Berkman Charles S | Former Executive Off | D - Sale to Iss | — | -11.9K | 23.8K | -33% | — |
| D | 2022-11-03 | 2022-11-01 | LGND | Berkman Charles S | Former Executive Off | D - Sale to Iss | — | -20.1K | 0 | -100% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-11-01 | D | D | 11,944 | — | 23,825 | D | — | — | (F1) Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022. |
| 2 | Derivative | Employee Stock Option (right to buy) | 2022-11-01 | D | D | 20,126 | — | 0 | D | $90.68 · — to 2032-05-05 | 20,126 Common Stock | (F1) Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022. (F2) The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter. |